



**AUSTIN HEART, P.L.L.C.
CLINICAL RESEARCH**

CURRICULUM VITAE

MISSION STATEMENT:

Austin Heart Clinical Research Program is dedicated to providing the most innovative and progressive care to our patient's, while at the same time, contributing to the science of medicine through the conduct of clinical trials.

SITE LOCATIONS:

PHONE NUMBERS:

1. Heart Hospital Office
3801 North Lamar, Suite 300
Austin, TX 78756

512-206-3600 – Main number
512-421-3827 – Fax

2. Medical Park Tower Office
1301 W. 38th Street
Austin, TX 78705

512-458-1006 – Main number
512-458-4876 – Fax

3. San Marcos Office
1330 Wonder World Drive, Suite B108
San Marcos, TX 78666

512-396-0889 – Main number
512-396-5623 – Fax

4. Killeen Office
2207 South Clear Creek Rd., Suite 304
Killeen, TX 76549

254-526-2085 – Main number
254-526-9569 – Fax

5. Round Rock Office
2410 Round Rock Avenue, Suite 110
Round Rock, Texas 78681

512-341-0889 – Main number
512-341-7147 - Fax

HOSPITAL AFFILIATIONS:

1. The Heart Hospital of Austin
3801 North Lamar
Austin, TX 78756

Ranked the #1 Hospital in the United States with the lowest Heart Attack Death rate of 10.9%

1.& 2. Seton Medical Center
1201 W. 38th St.
Austin, TX 78705

3. Central Texas Medical Center
1301 Wonder World Drive
San Marcos, TX 78666

4. Metroplex Hospital
2201 South Clear Creek Rd.
Killeen, TX 76549

5. St. David's Round Rock
2400 Round Rock Ave.
Round Rock, TX 78681

RESEARCH COMMITTEE:

Roger Gammon, MD

Polly Mock, RN, CCRC

Jeffrey Whitehill, MD

Steven Minor, MD

Thomas Carlson, MD

Richard Cashion, MD

Karen Gupton, Associate Administrator, Director of Clinical Operations

DEPARTMENT MANAGERS:

Roger Gammon, MD
Research Department Medical Director
512-206-3600
Heart Hospital Office

Polly Mock, RN, CCRC
Research Department Director
512-421-3851
All Research Sites
Heart Hospital Office

Mary Fraser, CCRC
Lead Clinical Research Coordinator
512-341-0889 X2812
All Research Sites
Round Rock Office

Bonnie Punske PhD
Clinical Research Specialist
512-421-3841
Heart Hospital Office

CLINICAL STAFF:

Paige Musick, RN, BSN, CCRC
Clinical Research Coordinator
512-421-3896

Heart Hospital Office

Melissa Samendinger, RN, BSN, CCRC
Clinical Research Coordinator
512-206-3614

Heart Hospital Office

Diana Bahm, RN
Clinical Research Coordinator
512-421-3877

Heart Hospital Office

Noona Tilton, RN
Clinical Research Coordinator
512-206-3602

Heart Hospital Office

Janet Hatch, MA
Clinical Research Coordinator
512-421-3860

Heart Hospital Office

Shannon Juarez
Research Assistant
512-206-3603

Heart Hospital Office

Lorie Tibbits, LVN
Clinical Research Coordinator
512-341-0889 X2807

Round Rock Office

Teresa Shipwash, RN, CCRC
Clinical Research Coordinator
512-396-5603 X2702

San Marcos Office

Rena Cherry, RN
Clinical Research Coordinator
254-526-2085

Killeen Office

FDA AUDIT:

Report Available Upon Request

RESEARCH EXPERIENCE:

Enrollment Closed:

- 5/95 – 10/95 ENTICES – Enoxaparin and Ticlopidine after Elective Stenting (multi-center, randomized trial). Sponsors: Rhone Poulenc Rorer & Mallinckrodt. 14 patients enrolled.
- 2/96 – 12/96 PURSUIT – Platelet IIb/IIIa Underpinning the Receptor for Suppression of Unstable Ischemia Trial (10,948 patient, multi-center, randomized trial). Sponsors: Cor Therapeutics Inc., & Schering Plough Corporation. 18 patients enrolled.
- 5/96 – 10/96 TECBEST – Transluminal Extraction Catheter Before Stent (500 patient, multi-center, randomized trial). Sponsor: University of Alabama at Birmingham. 6 patients enrolled.
- 6/96 – 1/97 ACUTE – Assessment of Cardioversion utilizing Transesophageal Echocardiography (2,900 patient, multi-center, randomized trial). Sponsors: National Institute of Health & Cleveland Clinic Foundation. 7 patients enrolled.
- 10/96 – 10/98 AVID – Angiography versus IVUS directed coronary stent placement; effect on long term clinical outcome. (multi-center, randomized trial). Sponsors: Scripps Research Foundation & Boston Scientific/SciMed. 23 patients enrolled.
- 5/97 – 9/97 MERIT – Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (multi-center, randomized trial). Sponsor: Astra Zeneca. 9 patients enrolled.
- 8/97 – 11/97 PARAGON– Paragon Stent Trial (1,000 patient, multi-center, randomized trial). Sponsor: Progressive Angioplasty Systems, Inc. 43 patients enrolled.
- 8/97 – 12/98 VAL-HeFT - Valsartan in Heart Failure Trial (4,310 patient, multi-center, randomized trial). Sponsor: Ciba-Geigy Corporation. 27 patients enrolled.
- 12/97 – 1/98 IMPRESS – Inhibition of Metallo Protease by BMS – 1867 in a randomized exercise and symptoms study. (532 patient multicenter randomized trial) Sponsors include Bristol-Myers Squibb. 3 patients enrolled.
- 12/97 – 9/99 MOST: Mode Selection Trial (2000 patient multicenter randomized trial) Sponsors include: National Institutes of Health. 8 patients enrolled.
- 12/97 – 2/98 WIZARD – Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorders (3300 patient, multi-center, randomized trial). Sponsor: Pfizer, Inc. 38 patients enrolled.
- 3/98 – 4/98 EXCITE – Evaluation of Xemilofiban in Controlling Thrombotic Events (multi-center, randomized trial). Sponsor: Searle. 16 patients enrolled.
- 6/98 – 6/99 TNT – Treating to New Targets (8600 patient multicenter randomized trial). Sponsors include: Parke-Davis and Pfizer, Inc. 37 patients enrolled.
- 7/98 – 1/05 GENECARD – Genetics of Early Onset Cardiovascular Disease (multi-center, registry trial). Sponsor: Duke University Medical Center, Center of Human Genetics. 7 families enrolled.

- 9/98 – 6/99 ALIVE - Azimilide Post-Infarction survival evaluation trial (2150 patient multicenter randomized trial) Sponsors include: Proctor and Gamble Pharmaceuticals, Inc. 5 patients enrolled.
- 12/98 – 10/99 CADILLAC – Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (2,000 patient, multi-center, randomized trial). Sponsors: Advanced Cardiovascular Systems, Inc. & Lilly Research Laboratories. 11 patients enrolled.
- 3/99 – 6/99 PARAGON B - Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network (5,200 patient, multi-center, randomized trial). Sponsor: F. Hoffmann-La Roche, Ltd. 10 patients enrolled.
- 3/99 – 10/99 RAFT - Rythmol® SR in Atrial Fibrillation Trial (450 patient, multi-center, randomized trial). Sponsor: Knoll Pharmaceuticals, Inc. 8 patients enrolled.
- 7/99 – 9/00 CURE – Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (9,000 patient, multi-center, randomized trial). Sponsors: Sanofi & Bristol Myers Squibb. 1 patient enrolled.
- 7/99 – 8/00 PRESTO – Prevention of Restenosis with Tranilast and its Outcome (11,500 patient, multi-center, randomized trial). Sponsor: SmithKline Beecham Pharmaceuticals. 125 patients enrolled.
- 8/99 – 4/01 Model 7250 - Investigational Arrhythmia Management Device (100 patient multicenter randomized trial) Sponsors include: Medtronic. 8 patients enrolled.
- 9/99 – 2/00 TRAFFIC – Therapeutic Angiogenesis with FGF for Intermittent Claudication (180 patient, multi-center, randomized trial). Sponsor: Chiron Corporation. 5 patients enrolled.
- 9/99 – 6/00 AMISTAD II - Acute Myocardial Infarction Study of Adenosine (2,100 patient, multi-center, randomized trial). Sponsor: Medco Research, Inc. 1 patient enrolled.
- 11/99 – 11/01 MADIT II - Multicenter Automatic Defibrillator Implantation Trial. Sponsor Guidant. 1 patient enrolled.
- 1/00 – 2/03 ATBAT – Anticoagulant Therapy with Bivalirudin to Assist in the performance of percutaneous coronary intervention in patients with heparin-induced Thrombocytopenia (100 patient, multi-center, open-label trial). Sponsor: The Medicines Company. 2 patients enrolled.
- 2/00 – 6/01 OVERTURE – Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (4840 patient multicenter randomized trial) Sponsors include: Bristol-Myers Squibb. 4 patients enrolled.
- 4/00 – 9/00 SAFER – Saphenous Vein Graft Angioplasty Free of Emboli Randomized Study (800 patient, multicenter, randomized trial) Sponsors include: PercuSurge Inc. 2 patients enrolled.
- 7/00 – 3/01 Device Far-field R-wave Discrimination- (A Randomized Prospective Study) Sponsor Medtronic. 10 patients enrolled.
- 8/00 – 4/01 CHESS – Comparative HDL Efficacy and Safety Study (multicenter randomized trial) Sponsors Include: Merck. 23 patients enrolled.
- 9/00 – 11/01 SPORTIF V: Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (3,000 patient, multi-center, randomized trial). Sponsor: Astra Zeneca. 30 patients enrolled.
- 9/00 – 7/01 Effect of Ad5FGF-4 on Myocardial Perfusion Defect Size and Safety in Patients with Stable Angina Study-303800 (50 patient, multi-center, randomized trial). Sponsor: Berlex Laboratories. 5 patients enrolled.

- 12/00 – 10/01 Response CV - A Randomized Comparison of Internal vs. External Cardioversion in Atrial Fibrillation. Sponsor: DAIG a St.Jude Medical Co. 6 patients enrolled.
- 12/00 – 7/01 ASSENT 3 – A Phase III Randomized, Open – Label Trial with 3 parallel groups: full dose TNK-tPA together with heparin sodium; full dose TNK-tPA together with enoxaparin; and half dose TNK-tPA together with abciximab and heparin sodium in patients with acute myocardial infarction.
- 1/01 – 2/01 REPLACE 1 – A Randomized Evaluation in PCI Linking Angiomax To Reduced Clinical Events (7,000 patient, multi-center, randomized trial) Sponsor: The Medicines Company. 9 patients enrolled.
- 2/01 – 5/02 P00693 – A Phase III Double-Blind Efficacy and Safety Study of SCH 59235 (10 mg) In Addition to Atorvastatin in Subjects with Coronary Heart Disease or Multiple Cardiovascular Risk Factors and with Primary Hypercholesterolemia Not Controlled by a Starting Dose (10 mg) of Atorvastatin
- 5/01 – 10/02 P01418 – Long-Term, Open-Label, Safety and Tolerability Study of SCH 58235 in Addition to Atorvastatin in subjects with Coronary Heart Disease or Multiple Risk Factors and with Primary Hypercholesterolemia Not Controlled by a Starting Dose (10mg) of Atorvastatin
- 6/01 – 3/02 NOET – TcN-Noet vs. Tc-Sestamibi (291 patient, multicenter, open label, single-crossover trial) Sponsors include CIS-US/Berlex Laboratories. 37 patients enrolled.
- 8/01 – 5/03 GREAT – Guided Radio Frequency Energy Ablation of Total Occlusions Using the Safe-Cross Radio Frequency Total Occlusion Crossing System (400 patient multicenter, randomized trial) Sponsors include: IntraLuminal Therapeutics, Inc. 34 patients enrolled.
- 9/01 – 3/02 Pre-CHILL - Evaluation of the safety and feasibility of the CVSi Cryoplasty System in patients undergoing percutaneous treatment of *de novo* and in-stent restenosis lesions in native coronary arteries (70 patient, multi-center, open-label trial). Sponsor: CryoVascular Systems Inc. 12 patients enrolled.
- 10/01 – 1/04 A Multi-center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina-304386 (450 patient multicenter randomized trial) Sponsors include: Berlex Laboratories. 6 patients enrolled.
- 10/01 – 9/03 Synergy – A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (8000 patients worldwide) Sponsors include: Aventis Pharmaceutical Products, Inc. 61 patients enrolled.
- 12/01 – 2/02 IMPACT – Kos Pharmaceuticals Inc. & Dupont Pharmaceuticals Company, “The Impact of Medical Subspecialty on Patient Compliance to Treatment”
- 1/02 – 3/02 REPLACE 2 - A Randomized Evaluation in PCI Linking Angiomax To Reduced Clinical Events, Part 2 (6,000 patient, multicenter, randomized trial) Sponsors Include: The Medicines Company. 25 patients enrolled.
- 1/02 – 2/04 PRIDE - Protection during saphenous vein graft intervention to prevent distal embolization (800 patient multicenter randomized trial). Sponsors Include: Kensey Nash Corporation. 12 patients enrolled.
- 1/02 – 3/02 DELIVER - Evaluation of the RX ACHIEVE™ drug coated coronary stent system in the treatment of patients with *de novo* native coronary artery lesions (1,042 patient, multi-center, randomized trial). Sponsor: Advanced Cardiovascular Systems (ACS) / Guidant Corporation. 15 patients enrolled.

- 6/02 – 3/03 Rosuvastatin 91 – A 48 Week Open-Label, Non-Comparative, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of the Lipid-Regulating Agent Rosuvastatin in the Treatment of Subjects With Fredrickson Type IIa and Type IIb Dyslipidemia. Sponsors include: Astra Zeneca. 4 patients enrolled.
- 7/02 – 3/05 I-PRESERVE – Irbesartan in Heart Failure With Preserved Systolic Function (3600 multicenter, randomized trial) Sponsors Include: Bristol-Myers Squibb and Sanofi-Synthelabo. 3 patients enrolled.
- 8/02 – 12/02 CVSi Peripheral Balloon Catheter System Safety Registry (100 patient multicenter non-randomized registry). Sponsors Include: CryoVascular Systems, Inc. 6 patients enrolled.
- 10/02 – 9/03 4522IL/0099 – A 6-week Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-group Study, Which Describes the Renal Effects of the Lipid-Regulating Agents Rosuvastatin and Simvastatin in the Treatment of Subjects with Fredrickson Type IIa, and Type IIb Dyslipidaemia, Including Heterozygous Familial Hypercholesterolaemia.
- 12/02 – 5/03 GRIP – Guided Radio Frequency in Peripheral Total Occlusions (50 patient multicenter non-randomized registry) Sponsors include: IntraLuminal Therapeutics, Inc. 7 patients enrolled.
- 12/02 – 6/03 PREVAIL – A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BO-653 in Prevention of Post-Angioplasty Restenosis in Stented Lesions. (600 patient, randomized trial). Sponsor: Chugai Pharmaceutical Co., Ltd. 13 patients enrolled.
- 1/03 – 10/04 DETECT SVT- Detection of SVT with Single Chamber vs. Dual Chamber Enhancements in Dual Chamber ICDs. Sponsor: St. Jude. 33 patients enrolled.
- 6/03 – 4/04 Clarity TIMI 28 – Clopidogrel as Adjunctive Reperfusion Therapy – Thrombolysis in Myocardial Infarction –28. A randomized, Double-Blind, Placebo-controlled trial comparing clopidogrel plus acetylsalicylic acid (ASA) versus ASA alone in subjects with acute ST elevation myocardial infarction (STEMI) treated with Fibrinolytic therapy. 11 patients enrolled.
- 8/03 – 9/03 GLIDELINE XR – A multi-center, prospective trial to evaluate the safety and effectiveness of the GLIDELINE XR Polyurethane leads. Sponsors include: Guidant. 11 patients enrolled.
- 8/03 – 9/04 INTRINSIC RV – A two-armed, randomized trial to compare the effects of innovative dual-chamber pacing with AVSH to standard VVI among ICD patients. (1250 patient, randomized trial). Sponsors include: Guidant. 36 patients enrolled.
- 8/03 - 5/05 TALON – A Prospective, Multi-Center, Observational Outcomes Database Registry. Sponsors include: FoxHollow. 196 patients enrolled.
- 8/03 – 6/05 ARISE – A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AGI-1067 in Reducing Cardiovascular Events in Patients with CAD. (4000 patient, randomized trial). Sponsor: AtheroGenics, Inc. 11 patients enrolled.
- 9/03 – 8/04 4522US/0007 – Starship – A 6wk, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the treatment of Hypercholesterolemia in Hispanic Subjects. 21 patients enrolled
- 10/03 – 6/04 DECREASE HF- Device Evaluation of CONTAK RENEWAL 2/4/4HE and EASYTRAK 2: Assessment of Safety and Effectiveness in Heart Failure. Sponsor: Guidant Corp. 3 patients enrolled.
- 12/03 – 6/05 COMBAT – A Non-Randomized Registry Study Using the FOXHOLLOW Coronary Debulking Catheter System in the Treatment of Bifurcation Lesions in Native Coronary Arteries (250 patient multicenter trial) Sponsors include: FOXHOLLOW. 3 patients enrolled.

- 12/03 – 7/05 AMADEUS – A Non-inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous Idraparinux with Adjusted-dose Oral Vitamin-K Antagonists in the Prevention of Thromboembolic Events in Patient with Atrial Fibrillation (600 patient, multicenter, randomized trial) Sponsors include: Organon. 110 patients enrolled.
- 12/03 – 7/05 ACUITY – A Randomized Comparison of Angiomax vs. Lovenox in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-segment Elevation (13,800 patient, randomized, multicenter trial) Sponsors include: The Medicines Company. 35 patients enrolled.
- 12/03 – 6/06 CVT 5131 – A Randomized, Double-Blind, Study of Intravenous CVT-3146 vs. Adenosine in Patients Undergoing Stress Myocardial Perfusion Imaging (855 patient multicenter trial) Sponsors include: CV Therapeutics, Inc. 24 patients enrolled.
- 8/04 – 2/05 REFLEX-A Randomized comparison of ENDOTAK RELIANCE G leads to all US market approved Guidant, Medtronic, St. Jude active-fixation dual coil endocardial defibrillation. 12 patients enrolled.
- 11/04 – 7/05 TRENDS- A post-marking study to evaluate the stroke risk predictive value stored in IPG, ICD, and CRT devices. Sponsor: Medtronic. 17 patients enrolled.
- 11/04 – 2/05 DISPERSE2 – TIMI 33 – A Double-blind, Double-dummy, Parallel Group Randomized Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes. 5 patients enrolled.
- 1/05 – 4/05 SITELINE- Clinical Investigation of SITELINE APL Silicone Pace/Sense Lead. Sponsor: Guidant Corp. 6 patients enrolled.
- 4/05 – 1/07 TRITON-TIMI 38 – A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo percutaneous Coronary Intervention (13,000 patient, randomized, multicenter trial) Sponsors include: Eli Lilly and Company. 31 patients enrolled.
- 4/05 – 10/05 ICE-PAF- Clinical Study to Evaluate the Safety and Efficacy of the CRYOCOR Cardiac Cryoablation System for the Treatment of Atrial Fibrillation. Sponsor: CryoCor Inc. 5 patients enrolled.
- 4/05 – 5/07 RIATA- Riata I integrated bipolar and Riata dedicated bipolar defibrillation leads in patients who have a standard indication for a CRT device. Sponsor: St. Jude. 9 patients enrolled.
- 5/05 – 5/05 EASYTRAK 4 STEERABLE Clinical Investigation of EASYTRAK 4 STEERABLE LV lead. Sponsor: Guidant Corp. 3 patients enrolled.
- 5/05 – 12/07 PEGASUS- A Randomized, Prospective, Single blind, Three Arm Study to Assess Atrial Support Pacing in a CRT Defibrillator Programmed to DDD-70, DDDR-40 compared to DDD-40. Sponsor: Guidant Corp. 24 patients enrolled.
- 7/05 – 7/06 ACROSS-Cypher – Approaches to Chronic Occlusions with Sirolimus Stents-Cypher (250 patient, multicenter trial) Sponsors include: David Kandzari, M.D. and Duke Clinical Research Institute. 8 patients enrolled.
- 7/05 – 10/05 Early ACS – Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome. 4 patients enrolled.
- 8/05 – 4/06 COSTAR II – Cobalt Chromium Stent with Antiproliferative for Restenosis II Trial (1700 patient, multicenter, randomized trial) Sponsors include: Conor Medsystems. 27 patients enrolled.

- 8/05 – 11/06 CAPTURE – Carotid RX ACCULINK/ACCUNET Post-Approval Trial to Uncover Unanticipated and Rare Events (500 patient, multi-center, observational, post-approval trial) Sponsors include: Guidant Corporation. 32 patients enrolled.
- 9/05 – 4/06 SPIRIT III – A Randomized, Multi-Center, Clinical Trial Evaluating the Safety and Efficacy of the XIENCE™ V Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects with de novo Native Coronary Artery Lesions. Sponsors include: Guidant Corporation. 2 patients enrolled.
- 10/05 – 1/06 ULTRA- Automatic Capture On versus patients randomized to automatic Capture OFF.(950 Patient, Prospective, Multi-center study) Sponsors include: Guidant. 5 patients enrolled
- 11/05 – 1/06 AFFECTS –Examine current physician practice in atrial fibrillation (AF) treatment (5,000 Patient, Open label, observational study) Sponsors include: Reliant Pharmaceuticals. 4 patients enrolled.
- 11/05 – 3/06 OSIRIS – A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation, Multi-center Study to Determine the Safety of Intravenous Ex-vivo Cultured Adult Human Mesenchymal Stem Cells (Provacel™) Following Acute Myocardial Infarction. (48 patient, randomized trial). Sponsors include Osiris Therapeutics. 5 patients enrolled.
- 1/06 – 10/06 PROVE - Programming ventricular tachycardia therapy for patients that need AICD. Sponsor: St Jude. 4 patients enrolled.
- 1/06 – 3/06 RED-TAIL – Registry of SFA Bilateral Disease Treated with the SilverHawk System. (Multi-center, prospective, outcomes database registry) Sponsors include: FoxHollow. 5 patients enrolled.
- 1/06 – 5/06 MERLIN – Multiple Lesions from a Unilateral Extremity Treated with SilverHawk in a Single Procedure. (Multi-center, prospective, outcomes database registry) Sponsors include: FoxHollow. 32 patients enrolled.
- 2/06 – 1/07 EXACT – Emboshield and Xact Post Approval Carotid Stent Trial (Multi-center, Observational, Single Arm, Post-Approval Study); Sponsors include: Abbott Vascular Devices. 18 patients enrolled.
- 3/06 – 12/07 RELY – Randomized, Evaluation of Long term Anticoagulant Therapy Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexialte with Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation: Prospective, Multi-center, Parallel-group, Non-inferiority Trial. (15,000 patient, randomized trial). Sponsors include Boehringer Ingelheim. 198 patients enrolled.
- 5/06 – 6/07 LEAP – A Two-part, Multi-center, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Effects of Simvastatin, Losartan, and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients with Peripheral Arterial Disease. Sponsor: FoxHollow. 8 patients enrolled.
- 6/06 – 1/07 SWIFT – Femoropopliteal Disease Treated With the SilverHawk Plaque Excision System: A Non-Randomized Registry with Duplex Ultrasound Follow Up At Twelve Months. Sponsor: FoxHollow. 8 patients enrolled.
- 7/06 – 12/07 PATRICIA – A Multi-center, Randomized, Open-Label Trail of Intra-Renal Fenoldopam Mesylate Vs. Intravenous Sodium Bicarbonate and Oral N-acetylcysteine in Patients at High Risk for Contrast Induced Nephropathy Undergoing Peripheral Vascular Intervention. Sponsor: FlowMedica. 2 patients enrolled.

- 9/06 – 6/07 FOCUS – Follow up Of Clinical Outcomes: The Long-term AGI-1067 plus Usual Care Study (Patients that wish to continue from the ARISE Study) Sponsors include: AtheroGenics, Inc. 9 patients enrolled.
- 3/07 – 12/07 BROADWING- “Biological Waste MateRial and Outcomes Analysis of Lower Extremity Peripheral Disease Treated With the SilverHawk™ Plaque ExcisioN System: A Tissue and Data ReGistry” Sponsor: FoxHollow. 1 patient enrolled.
- 8/07 – 12/07 NIGHTHAWK – Evaluation of the NightHawk peripheral excision system for patients with infrainguinal lesions. (20 patient, non-randomized, multicenter trial) Sponsors include: FoxHollow Technologies, Inc. 15 patients enrolled.
- 10/07 – 10/07 PLASMA 2 – Phospholipase Levels And Serological Markers of Atherosclerosis 2 (120 patient, randomized, double-blind, placebo-controlled trial) Sponsors include: Anthera Pharmaceuticals, Inc. 6 patients enrolled.
- 2/08 – 5/08 POINT 3 – A Clinical Trial to Assess Perfusion and Obstruction Identified by Non-Invasive Technology Using PB127 Ultrasound Contrast Agent in Patients with Suspected Obstructive Coronary Artery Disease II (850 patient, open label, multicenter trial) Sponsors include: POINT Biomedical Corporation. 4 patients enrolled.
- 6/07 – 6/08 PROTECT – Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (320 patient, multicenter, non-randomized trial) Sponsors include: Abbott Vascular. 17 patients enrolled.
- 12/06 – 7/08 PLATO – A Study of PLATelet inhibition and Patient Outcome (18,000 patient, multicenter, randomized, double-blind trial) Sponsors include: AstraZeneca. 60 patients enrolled.
- 1/08 – 9/08 PASCAL – Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Capabilities (140 patient, randomized, double-blind, placebo-controlled trial) Sponsors include: ARYx Therapeutics. 2 patients enrolled.
- 9/08 – 12/08 XIENCE V – Everolimus Eluting Coronary Stent System USA Post-Approval Study (5000 patient, open-label, multicenter, single-arm registry) Sponsors include: Abbott Cardiovascular Systems, Inc. 126 patients enrolled.
- 12/06 – 3/09 RESPECT - Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (400 patient, post-approval trial) Sponsors Include: Medtronic. Heart Hospital office. 7 patients enrolled.
- 1/09 – 3/09 RELY-Able – Long Term Multi-center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation Who Completed the RE-LY Trial. Sponsors include: Boehringer Ingelheim Heart Hospital, San Marcos, MPT and Killeen. 89 patients enrolled
- 1/08 – 4/09 EMINENCE – Evaluation of M118 in Percutaneous Coronary Intervention (600 patient, multicenter, randomized, open-label trial) Sponsors include: Momenta Pharmaceuticals. Heart Hospital, 45 patients enrolled.
- 3/08 – 4/09 AFI-30 – Tailored Treatment of Permanent Atrial Fibrillation (210 patient, multicenter, randomized trial) Sponsors include: Ablation Frontiers. 14 patients enrolled.
- 1/08 – 4/09 PACE MI – Pacemaker and Beta-Blocker Therapy after Myocardial Infarction Trial (562 patient, multicenter, randomized trial) Sponsors include: Dr. Jeff Goldberger at Northwestern University and National Institutes of Health.
- 3/07 – 5/09 CHAMPION Platform – Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (4400 patient, multicenter, randomized trial) Sponsors include: The Medicines Company. 39 patients enrolled.

- 10/7 – 7/09 OM8 – To Assess the Efficacy and Safety of Omacor for the Prevention of Recurrent, Symptomatic Atrial Fibrillation (660 patient, randomized, double-blind, placebo-controlled trial) Sponsors include: Reliant Pharmaceuticals, Inc. 14 patients enrolled
- 4/09 – 9/09 PLATINUM – Everolimus-Eluting Coronary Stent for the treatment of coronary lesions (1532 patient, prospective, randomized, multicenter study) Sponsors include Boston Scientific. Heart Hospital office. 7 patients enrolled.
- 4/09 – 9/09 STABILITY – Darapladib vs. placebo in chronic CHD patients with first MACE event (15,500 patient, randomized, double-blind, parallel group, multi-center study) Sponsors include; GlaxoSmithKline Killeen office. 13 patients enrolled.
- 11/07 – 11/09 TIMI 50 – Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (20,000 patient, randomized, double blind, placebo-controlled, multinational trial) Sponsors include: Schering-Plough Research Institute. Heart Hospital, MPT, San Marcos and Killeen offices. 110 patients enrolled.
- 11/08 – 1/10 SMART AV – Smart Delay compared to other AV delay methods used in CRT. (950 patient, randomized, multi-center, double-blind, 3 arm trial) Sponsors include: Boston Scientific. Heart Hospital and Round Rock offices. 47 patients enrolled.
- 1/10 – 2/10 RAAFT - First Line Radiofrequency Ablation versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment: (400 Patient, Multi-center Randomized Trial) Sponsors include: Andrea Natale, M.D. Heart Hospital office. 3 patients enrolled.
- 12/09 – 2/10 Spirit PRIME – XIENCE PRIME and XIENCE PRIME LL for treatment of coronary lesions. (500 Patient, Prospective, two-arm, open-label, multi-center Registry) Sponsors include: Abbott Cardiovascular Systems Inc. Heart Hospital office. 4 patients enrolled.
- 1/10 – 3/10 STROLL – S.M.A.R.T.TM Nitinol Self-Expandable Stent System in treating patients with SFA disease. (250 Patient, Multi-center, non-randomized, single-arm, prospective trial). Sponsors include: Cordis. Heart Hospital office. 0 patients enrolled.
- 3/09 – 4/10 GRAVITAS – VerifyNow Assay for pts that (1532 patient, prospective, randomized, multicenter study) Sponsors include Accumetrics and Synteract. Heart Hospital office. 27 patients enrolled.
- 10/08 – 6/10 Dal-Outcomes – RO4607381 on cardiovascular risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (15,600 patient, double-blind, randomized, placebo-controlled study) Sponsors include: Hoffman La-Roche, Inc. Heart Hospital, San Marcos, and Round Rock offices. 68 patients enrolled
- 3/06 – 7/10 IMPROVE- IT – IMProve Reduction of Outcomes: Vytarin Efficacy International Trial (10,000 patient, multicenter, double-blind, randomized trial) Sponsors include: Schering-Plough Research Institute. Heart Hospital and San Marcos offices. 59 patients enrolled.
- 8/09 – 9/10 PROVIDE – Programming Implantable Cardioverter Defibrillators to Prolong Time to First Shock (1600 patient, randomized, multicenter study) Sponsors include: St. Jude. Round Rock office. 44 patients enrolled.
- 9/09 – 10/10 Definitive Ca++ – SilverHawk LS-C with the SpiderFX in lower extremity PAD undergoing plaque excision. (102 patient, prospective, multi-center, non-randomized, single-arm study) Sponsors include: EV3. Heart Hospital office. 13 patients enrolled.
- 3/09 – 12/10 OSIRIS – A Phase II, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL[®] intravenous infusion following acute myocardial infarction (220 patient, randomized trial). Sponsors include: Osiris Therapeutics. Heart Hospital office. 22 patients enrolled.

- 9/08 – 1/11 ENDEAVOR – Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single De novo Lesions in Small Diameter Native Coronary Arteries (300 patient, prospective, multicenter, open-label trial) Sponsors include: Medtronic Heart Hospital office. 3 patients enrolled.
- 2/11 – 3/11 CONNECT - Chronic Total Occlusion Crossing with the WildCat Catheter (77 Patient, Prospective, Multi-center, Non-randomized trial) Sponsors include: Avinger. 4 patients enrolled
- 1/10 – 4/11 SOLSTICE – GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with STEMI (500 Patient, Randomized, Double-blind, Placebo-controlled study) Sponsors include: GlaxoSmithKline. Heart Hospital and Round Rock office. 9 patients enrolled.
- 9/09 – 5/11 SUPERB – SUPERA Nitinol Stent System in treating subjects with obstructive SFA disease. (258 Patient, Prospective, Multi-center, Non-randomized, Single-arm Trial) Sponsors include: Idev Technologies Inc. Heart Hospital office. 17 patients enrolled.
- 2/10 – 7/11 DAPT – Dual Anti-platelet therapy in subjects undergoing PCI with either DES or BMS placement for the treatment of coronary artery lesions. 20,645 Patient, Multi-center, Randomized, Double-blind Trial) Sponsors include: HCRI . Heart Hospital office. 62 patients enrolled.
- 2/11 – 9/11 SAVOR TIMI 53 - Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus. (12,000 Patient, Multi-Center, Double-Blind, Placebo-Controlled Trial) Sponsors include: AstraZeneca & Bristol Myers Squibb. 13 patients enrolled
- 5/10 – 10/11 SOLID – TIMI 52 - The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 (11,500 Patient, Multi-center, Randomized, Double-blind Trial) Sponsors include: GlaxoSmithKline. Heart Hospital office, MPT, Round Rock, San Marcos and Killeen. 35 patients enrolled.
- 2/07 – 3/12 CHOICE – Carotid Stenting for High Surgical-Risk Patients; Evaluating Outcomes Through Collection of Clinical Evidence (Open ended enrollment, non-randomized, multicenter trial) Sponsors include: Abbott Vascular. Heart Hospital office. 297 patients enrolled.
- 2/12 – 4/12 REVEAL – Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (30,000 Patient, Multi-center, Worldwide, Randomized Trial) Sponsors include: Oxford University, The TIMI Group and Merck. patients enrolled.

Open for Enrollment:

- 9/06 – Present ACT I – Carotid Angioplasty and Stenting versus Endarterectomy in Asymptomatic Subjects with Significant Extracranial Carotid Occlusive Disease (1540 patient, multicenter, randomized trial) Sponsors include: Abbott Vascular. Heart Hospital office. 74 patients enrolled.
- 11/09 – Present ACUITY – Longitudinal Surveillance Registry of the ACUITY Spiral Lead. (1700 Patient, Prospective, Non-Randomized Registry) Sponsors include: Boston Scientific. Heart Hospital office. 6 patients enrolled.
- 8/08 – On Hold RBM – Luminex xMAP (multianalyte profile) to diagnose ACS patients using blood biomarker profiles (200 patient, single-center study) Sponsors include: Rules Based Medicine. Heart Hospital office. 178 patients enrolled.
- 1/10 – Present MADIT-RIT – Multicenter Automatic Defibrillator Implantation Trial: Reduce Inappropriate Therapy. (1500 Patient, Prospective, Randomized, 3-arm trial) Sponsors include: Boston Scientific. Heart Hospital office. 35 patients enrolled.

- 9/10 – Present MultiSENSE - Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients (450 Patient, Multi-Center, Non-randomized, Prospective Trial) Sponsors include: Boston Scientific CRM. 9 patients enrolled.
- 1/11 – Present PEGUSUS TIMI 54 - Prevention with Ticagrelor of Secondary Thrombotic Events in High-Risk Patients with Prior Acute Coronary Sndrome. (13,500 patient, Randomized, Double-blind, Placebo-controlled trial) Sponsors include AstraZeneca 7 patients enrolled
- 2/11 – Present BioMet - MarrowStim™ PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects with Severe PAD (152 patient, Double-Blind, Placebo-Controlled, Multi-Center Trial) Sponsors include: Biomet Biologics. 0 patients enrolled.
- 2/11 – Present CHAMPION Phoenix - Cangrelor versus standard therapy to achieve optimal management of platelet inhibition. (10,900 patient, Randomized, double blind, placebo-controlled trial) Sponsors include: The Medicines Company. 126 patients enrolled
- 6/11 – Present Levant 2 – Moxy™ Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries. (500 Patient, Prospective, Multi-center, Single-Blind, Randomized, Trial) Sponsors include: Lutonix, Inc. 19 patients enrolled.
- 7/11 – Present RESPECT – VASCADE™ Vascular Closure System (VCS) vs. Manual Compression for the Management of the Femoral Arteriotomy after Percutaneous Endovascular Procedures (420 Patient, Multi-center, Prospective, Randomized Trial) Sponsors Include: Cardiva. 66 patients enrolled.
- 7/11 – Present Tryton – Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side-branch Balloon Angioplasty in Conjunction with a Drug-eluting Stent in the Treatment of de novo Bifurcation Lesions Involving the Main Branch and Side Branch within Native Coronary Circulation. (704 Patient, Multi-center, Single-Blind, Randomized Trial) Sponsors include: Tryton Medical, Inc. 8 patients enrolled.
- 3/12 – Present Symplicity HTN-3 – Renal Denervation in Patients with Uncontrolled Hypertension (1060 Patient, Multi-center, Blinded, Randomized Trial) Sponsors include: Medtronic Ardian. 5 patients enrolled.
- 4/12 – Present Laptop – Left Atrial Pressure Monitoring to Optimize Heart Failure (730 Patient, Multicenter, Randomized Trial). Sponsors include: St. Jude Medical. 2 patients enrolled
- 5/12 – Present EXCEL – Evaluation of Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (3500 Patient, Multi-center, Prospective, Randomized Trial) Sponsors include: Abbott Vascular. 0 patients enrolled.
- 5/12 – Present RAID – Ranolazine ICD Trial Late Sodium Current Blockade in High-Risk ICD Patients. (1440 Patient, Randomized, Double-blind, Placebo-controlled trial) Sponsors include: NIH. 1 patients enrolled.
- 7/12- Present Connect II
- 9/12- Present Accent MRI -